The dominant host system for producing therapeutic recombinant proteins over the last few decades has been the mammalian expression system.

The benefit of this system includes: 

  • Highest capacity for generating complex post-translational modifications (PTMs) compared to other expression systems
  • High success rate of soluble protein recovery
  • Suitable for antibody production

One of the main drawbacks of the system is the increased expense when compared to other systems such as bacteria.